Search Results

Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its Biologic License Application approval by the U.S. Food and Drug Administration on June 13, 2024.

Grifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration for Yimmugo®, an innovative intravenous immunoglobulin therapeutic, to treat primary immunodeficiencies.

Grifols, one of the world’s leading producers of plasma-derived medicines, announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin Yimmugo® during the next seven years, following recent Food and Drug Administration approval to treat primary immunodeficiencies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.